Nevro Corp
United States
About Nevro Corp
225 articles about Nevro Corp
-
Nevro Enters Into Cooperation Agreement With Engaged Capital
2/21/2024
Nevro Corp. announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC, pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors as well as the Audit Committee of the Board effective February 20, 2024.
-
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
1/18/2024
Nevro Corp. announced that Carelon Healthcare, a healthcare services company dedicated to delivering whole-person care with connected healthcare solutions for better outcomes and experiences, will be publishing a new interventional pain management policy that expands spinal cord stimulation coverage for painful diabetic neuropathy.
-
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
1/9/2024
Nevro Corp. today announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results.
-
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/4/2024
Nevro Corp. announced that members of its management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.
-
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain
11/20/2023
Nevro Corp. today announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine.
-
Nevro to Report Third Quarter 2023 Financial Results
10/4/2023
Nevro Corp. today announced that the company will report its financial results for third quarter ended September 30, 2023 after the market closes on November 1, 2023.
-
Nevro Announces Participation in Upcoming Investor Conferences - August 23, 2023
8/23/2023
Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences.
-
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
8/16/2023
Nevro Corp. today announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, in Diabetes Research and Clinical Practice.
-
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
8/1/2023
Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, reported its second quarter 2023 financial results.
-
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
7/13/2023
Nevro Corp. today announced that 24-month data from the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT).
-
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
7/12/2023
Nevro Corp. today announced that Kevin Thornal , Nevro's CEO and President, and Rod MacLeod , Nevro's CFO, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 8:30 am Eastern Time at the InterContinental Boston Hotel in Boston, MA.
-
Nevro to Report Second Quarter 2023 Financial Results
6/27/2023
Nevro Corp. today announced that the company will report its financial results for the second quarter ended June 30, 2023 after the market closes on August 1, 2023.
-
Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
6/23/2023
Nevro Corp. today announced that data from an analysis of the 24-Month SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial (RCT), the largest RCT to evaluate spinal cord stimulation (SCS) to treat PDN, will be presented at the American Diabetes Association (ADA) 83rd Scientific Sessions to be held June 23-26, 2023 in San Diego, CA.
-
Nevro Names New Chief Commercial Officer - June 05, 2023
6/5/2023
Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that Greg Siller has been appointed Senior Vice President and Chief Commercial Officer of Nevro, effective June 19, 2023.
-
Nevro to Present at Jefferies Healthcare Conference
5/22/2023
Nevro Corp. today announced that Kevin Thornal, Nevro's CEO and President, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 10:30 am Eastern Time at the Marriott Marquis Hotel in New York, NY.
-
Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual
4/27/2023
Nevro Corp. announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock and performance unit awards covering 135,623 shares of its common stock to Kevin Thornal, who joined Nevro as its Chief Executive Officer & President, in connection with his commencement of employment.
-
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
4/26/2023
Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, reported its first quarter 2023 financial results.
-
Nevro Announces Participation in Upcoming Investor Conferences - April 24, 2023
4/24/2023
Nevro Corp. announced today that it is participating in the following investor conferences.
-
Nevro Announces Enrollment of First Patient in PDN Sensory Study
4/24/2023
Nevro Corp. (NYSE: NVRO) today announced that it has enrolled the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, which is the first prospective randomized controlled trial (RCT) to assess restoration of neurological function as a primary objective in patients with intractable PDN.
-
Nevro Names Kevin Thornal as New Chief Executive Officer and President
4/19/2023
Nevro Corp. announced that Kevin Thornal has been appointed Chief Executive Officer and President of Nevro, effective April 24, 2023, and will also be appointed to the Board of Directors.